Natera (NTRA) president sells 915 shares to cover RSU taxes

Rhea-AI Filing Summary

Natera, Inc. president of clinical diagnostics Solomon Moshkevich reported compensation-related stock activity. He received 1,774 fully vested Restricted Stock Units (RSUs), each representing the right to one share of Natera common stock. The next day, he sold 915 shares of common stock at $204.1327 per share.

The sale was carried out to satisfy tax withholding and remittance obligations arising from the RSU vesting and was made under a written instruction intended to meet the Rule 10b5-1(c) affirmative defense conditions in his March 9, 2026 stock unit agreement. After these transactions, he directly held 150,882 shares of Natera common stock.

Insider Trade Summary 10b5-1

Net Seller: 915 shares ($186,781)

Net Sell 2 txns

Insider Moshkevich Solomon

Role PRESIDENT, CLINICALDIAGNOSTICS

Sold 915 shs ($187K)

Type	Security	Shares	Price	Value
Sale	Common Stock	915	$204.1327	$187K
Grant/Award	Common Stock	1,774	$0.00	--

Holdings After Transaction: Common Stock — 150,882 shares (Direct)

Footnotes (1)

1. Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person. The RSUs were fully-vested at the time of issuance. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on March 9, 2026.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moshkevich Solomon

(Last) (First) (Middle)

C/O NATERA, INC.

13011 MCCALLEN PASS BUILDING A SUITE 100

(Street)

AUSTIN TX 78753

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Natera, Inc. [ NTRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT, CLINICALDIAGNOSTICS

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		A		1,774(1)	A	(2)	151,797	D
Common Stock	03/10/2026		S		915(3)	D	$204.1327	150,882	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person. The RSUs were fully-vested at the time of issuance.

2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

3. The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on March 9, 2026.

	/s/ Tami Chen, Attorney-in-Fact	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Natera (NTRA) report for Solomon Moshkevich?

Solomon Moshkevich reported two transactions: a grant of 1,774 fully vested RSUs and an open-market sale of 915 common shares at $204.1327 per share. These actions reflect equity compensation and a related share sale.

Why did Solomon Moshkevich sell 915 Natera (NTRA) shares?

He sold 915 shares to satisfy tax withholding and remittance obligations tied to the vesting of RSUs. The sale followed a written instruction intended to meet Rule 10b5-1(c) affirmative defense conditions in his stock unit agreement dated March 9, 2026.

How many Natera (NTRA) shares does Solomon Moshkevich hold after these transactions?

Following the reported transactions, Solomon Moshkevich directly holds 150,882 shares of Natera common stock. This figure reflects his position after receiving 1,774 fully vested RSUs and selling 915 shares to cover associated tax obligations from the RSU vesting.

What did the RSU grant to Solomon Moshkevich at Natera (NTRA) involve?

He received 1,774 Restricted Stock Units (RSUs) that were fully vested upon issuance. Each RSU represents a contingent right to receive one share of Natera common stock, effectively adding equity-based compensation to his holdings when delivered.

Was Solomon Moshkevich’s Natera (NTRA) share sale pre-arranged under Rule 10b5-1?

The filing states the sale was made under a written instruction intended to satisfy Rule 10b5-1(c) affirmative defense conditions. This indicates the sale was pre-arranged within his March 9, 2026 stock unit agreement rather than decided spontaneously.

What role does Solomon Moshkevich hold at Natera (NTRA)?

Solomon Moshkevich is identified as President, Clinical Diagnostics at Natera. His reported equity transactions involve Natera common stock and RSUs, reflecting compensation and related tax obligations for a senior executive in the company’s clinical diagnostics segment.